Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
154.25B
Market cap154.25B
Price-Earnings ratio
18.80
Price-Earnings ratio18.80
Dividend yield
2.60%
Dividend yield2.60%
Average volume
4.27M
Average volume4.27M
High today
$124.69
High today$124.69
Low today
$121.30
Low today$121.30
Open price
$122.49
Open price$122.49
Volume
6.18M
Volume6.18M
52 Week high
$128.70
52 Week high$128.70
52 Week low
$88.57
52 Week low$88.57

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $124.22, giving the company a market capitalization of 154.25B. It carries a P/E multiple of 18.80 and pays a dividend yield of 2.6%.

On 2026-01-08, Gilead Sciences(GILD) stock moved within a range of $121.30 to $124.69. With shares now at $124.22, the stock is trading +2.4% above its intraday low and -0.4% below the session's peak.

Trading activity shows a volume of 6.18M, compared to an average daily volume of 4.27M.

The stock's 52-week range extends from a low of $88.57 to a high of $128.70.

The stock's 52-week range extends from a low of $88.57 to a high of $128.70.

GILD News

Simply Wall St 14h
What Gilead Sciences's OncoNano Drug-Encapsulation Deal Means For Shareholders

OncoNano Medicine recently announced a research collaboration with Gilead Sciences to test its ON-BOARD encapsulation technology with a Gilead drug candidate, w...

What Gilead Sciences's OncoNano Drug-Encapsulation Deal Means For Shareholders
TipRanks 1d
Gilead Sciences: PrEP-Led Growth, Easing HIV Overhangs, and Pipeline Upside Support Buy Rating and 2027 Re-Rating Target

UBS analyst Michael Yee maintained a Buy rating on Gilead Sciences yesterday and set a price target of $145.00. Claim 70% Off TipRanks Premium Unlock hedge fund...

Simply Wall St 2d
Assessing Gilead Sciences Valuation After Mixed Near Term Returns And 9.4% Undervaluation Estimate

Advertisement Why Gilead Sciences is on investors’ radar today Gilead Sciences (GILD) has been drawing attention after recent share moves, with the stock clos...

Assessing Gilead Sciences Valuation After Mixed Near Term Returns And 9.4% Undervaluation Estimate

Analyst ratings

76%

of 29 ratings
Buy
75.9%
Hold
24.1%
Sell
0%

More GILD News

Nasdaq 3d
Gilead Sciences Stock Declines While Market Improves: Some Information for Investors

In the latest market close, Gilead Sciences (GILD) reached $72.41, with a -0.21% movement compared to the previous day. The stock fell short of the S&P 500, whi...

Gilead Sciences Stock Declines While Market Improves: Some Information for Investors
TipRanks 3d
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million

Claim 70% Off TipRanks This Holiday Season Repare Therapeutics ( (RPTX) ) has issued an announcement. Repare Therapeutics has entered into an asset purchase a...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.